Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of methylphenidate for treating
hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with
Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and
Drug Administration for the treatment of children and adolescents with Attention Deficit
Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD
symptoms in PDD are limited. Children and adolescents who do not show a positive response to
methylphenidate will be invited to participate in a pilot study of the non-stimulant
medication guanfacine (Tenex).